A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection
Clinical Trial Grant
Administered By
Medicine, Gastroenterology
Awarded By
Rebiotix Inc.
Start Date
April 12, 2021
End Date
April 11, 2024
Administered By
Medicine, Gastroenterology
Awarded By
Rebiotix Inc.
Start Date
April 12, 2021
End Date
April 11, 2024